Mobile phase A was 0.05% formic acid aqueous solution, and mobile phase B was 23 methanol containing 0.05% formic acid. Mobile phase program was isocratic flow (0.3 24 mL/min) of mobile phase A/B (3/7). The retention times of amiselimod, amiselimod-P, 25 fingolimod and fingolimod-P were 2.5, 2.4, 3.5 and 3.2 min, respectively. 26
27
Clinical 28
The concentrations of plasma amiselimod and amiselimod-P were measured using a 29 fully validated LC/MS/MS. 30
For determination of amiselimod and amiselimod-P, blood samples were 31 collected into polypropylene tubes containing dipotassium-ethylenediamine-tetra acetic 32 acid (K2-EDTA) at each scheduled time-point. Samples were centrifuged at 1500 g for 33 injected into the LC/MS/MS system. 37 Effects of amiselimod-P, fingolimod-P, and S1P on human GIRK currents 51 GIRK currents recorded in human atrial myocytes were measured using the whole-cell 52 patch clamp method. Representative trace at −100 mV illustrating the effects of S1P 53 (A), fingolimod-P (B), and amiselimod-P (C) on GIRK currents. 54 55 100 pA 100 pA 100 pA Effect of amiselimod on heart rate in cynomolgus monkeys 59
Amiselimod was orally administered to conscious male cynomolgus monkeys in a dose-60 ascending manner at dose levels of vehicle, 0.3, 3 and 30 mg/kg, with a 6-day interval 61 between vehicle and 0.3 mg/kg, and 13-or 14-day intervals between dose levels of 0.3, 62 3 and 30 mg/kg. Heart rate and ECG were analysed before and at 4, 8, 24, 48 and 72 h 63 after each dose using the telemetry system. Results are expressed as the mean ± SD 64 (n=4). 65 66
Supplemental Figure 3 67
Effects of 0.75 mg of amiselimod on mean hourly heart rate in healthy subjects.
68
Mean hourly heart rate was measured by 24-hour 12-lead Holter ECG. Curves on day 1 69 to day 21 are shown as pink bands, and the curve on day −1 as the blue band. 
